We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Esophageal Cancer GWAS Leads to Risk Variants

By LabMedica International staff writers
Posted on 15 Feb 2018
Genome-wide association studies have identified common variants associated with risk of esophageal squamous cell carcinoma; however, these common variants cannot explain all heritability of esophageal cancer.

New germline contributors to esophageal squamous cell carcinoma (ESCC) risk have been revealed, including a low-frequency change to the Cytochrome P450 Family 26 Subfamily B Member 1, (CYP26B1) drug metabolism gene that appears to affect blood serum levels of a tumor suppressor called all-trans retinoic acid (atRA).

Scientists at the Chinese Academy of Medical Sciences (Beijing, China) and their colleagues used exome sequences for more than 3,700 individuals with ESCC and nearly 3,900 individuals without. More...
They looked for single-nucleotide polymorphisms (SNPs) or low-frequency variants associated with risk of the disease, which is especially common in parts of China. From these data, they narrowed in on half a dozen risk sites that could be replicated in another 7,002 cases and 8,757 controls, including three common SNPs and three low-frequency variants.

The team used Illumina HumanExome BeadChip arrays to profile low-frequency protein-coding variants in the ESCC cases and the controls from Beijing. After excluding samples with insufficient or low-quality data, they were left comparing exome patterns for 3,714 of the ESCC cases and 3,880 controls, an analysis that led to 30 suspicious variants. The team attempted to verify the potential ESCC risk variants with OpenArray- or TaqMan-based genotyping on individuals from two replication cohorts: 3,120 ESCC cases and 3,919 controls from Wuhan province and another 3,882 individuals with ESCC and 4,838 without from the Chinese province of Hebei.

The scientists uncovered six new risk variants at four sites in or around the CCHCR1, TCN2, TNXB, LTA, CYP26B1, and FASN genes. Three of the associations at the TCN2, CYP26B1, and FASN gene loci, were based on low-frequency variants that appeared to have higher-than-usual effect sizes. An ESCC-associated variant at CYP26B1, called rs138478634, had particularly close ties to ESCC risk in individuals with a history of smoking and/or drinking, although the team noted that rs138478634 was not linked to smoking or drinking status in control individuals. Through a series of follow-up cell line and patient serum expression profiling experiments, the group saw lower-than-usual levels of the atRA tumor suppressor in cells or individuals pumping out the rs138478634 variant-containing version of CYP26B1.

The authors concluded that results of the new study extended previous findings and advanced our understanding of the genetic etiology of ESCC, which might be useful for risk assessment, early detection, and targeted treatment of ESCC. The study was published on January 29, 2018, in the journal Nature Genetics.

Related Links:
Chinese Academy of Medical Sciences


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.